Pfizer has started a study of its COVID-19 pill in children who have COVID-19 and are designated as high-risk for experiencing severe symptoms. The phase 2/phase 3 study has approximately 140 participants between the ages of 6 and 17. One cohort will receive Pfizer’s pill, known as Paxlovid or nirmatrelvir, twice a day for five days. The other group will follow the same schedule, but receive a dosage equal to half as much. Both cohorts will also take ritonavir, an antiviral drug. Pfizer says the pill is needed because although children are less likely to require hospital care after contracting COVID-19, the disease caused by the CCP (Chinese Communist Party) virus, a number of kids have been hospitalized with COVID-19 during the pandemic. “There is a significant unmet need for outpatient treatments that can be taken by children and adolescents to help prevent progression to severe illness, including hospitalization or death,” Mikael Dolsten, » Read full article
Sperm Counts Halved, Is This Diet-Switch Triggering an Apocalypse?
Analysis by Ashley Armstrong Story at-a-glance Male fertility is declining sharply, with sperm counts dropping over 50% in the last 50 years The shift from saturated fats to polyunsaturated
